Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abatacept - Bristol-Myers Squibb

Next Previous
X
Search
Drug Profile

Abatacept - Bristol-Myers Squibb

Alternative Names: Abata - Bristol-Myers Squibb; BMS-188667; BMS-188667SC; CTLA4-Ig; hCTLA4-Ig-Bristol-Myers-Squibb; ONO-4164; ONO-4164-IV; ONO-4164-SC; Orencia; Orencia IV; Orencia SC

Latest Information Update: 23 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cambridge University Hospitals; Columbia University; National Institute for Health Research; National Institute of Allergy and Infectious Diseases; Ono Pharmaceutical; Simcere Pharmaceutical Group; University Hospital, Brest; University Medical Center Freiburg; University Medical Center Groningen; University of Michigan; University of Pittsburgh
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoglobulin fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Skin disorder therapies; Urologics
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Giant cell arteritis; Myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Registered Graft-versus-host disease
  • Phase III COVID 2019 infections; Dermatomyositis; Lupus nephritis; Myositis; Polymyalgia rheumatica; Polymyositis
  • Phase II Alopecia areata; Common variable immunodeficiency; Diffuse scleroderma; Interstitial lung diseases; Nephrotic syndrome; Pulmonary sarcoidosis
  • No development reported Ulcerative colitis
  • Discontinued Crohn's disease; Inflammation; Multiple sclerosis; Psoriasis; Sjogren's syndrome; Systemic lupus erythematosus; Transplant rejection; Xenotransplant rejection

Most Recent Events

  • 12 Jun 2024 Adverse events and efficacy data from a phase III trial in Myositis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 12 Jun 2024 Efficacy and adverse event data from a phase III trial in Rheumatoid arthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 31 Mar 2024 Boston Children's Hospital completes a phase-II trial in Graft-versus-host disease (Prevention, Combination therapy) in Canada, USA (IV) (NCT01743131)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top